# NCT01375842 (NCT01375842)

> A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

No report yet. It can be ordered.

- Drugs tested: atezolizumab
- Indication: advanced solid tumors or hematologic malignancies

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01375842
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Genentech, Inc.
- Conditions: Tumors; Hematologic Malignancies
- Interventions: Atezolizumab
- Enrollment: 661
- Primary outcome: Number of Participants With Dose Limiting Toxicities (DLTs)
- Primary outcome: Maximum Tolerated Dose (MTD) of Atezolizumab
- Primary outcome: Recommended Phase 2 Dose (RP2D) of Atezolizumab
- Primary outcome: Percentage of Participants With Adverse Events

## Indexed commentary on NCT01375842 so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct01375842
